Figure 2. PTPRG and PTPRC modulate nilotinib and imatinib response in cell lines.

IC₅₀ analyses for nilotinib (A, D), imatinib (B, E), and dasatinib (C, F) were carried out with K562 cells stably expressing wild type PTPRG (WT) or catalytically inactive PTPRG-C1060S mutant (CS) (A, B, C) or with two individual clones (A and B) of K562 cells subjected to CRISPR/Cas9 mediated knockout of PTPRC gene and corresponding CRISPR/Cas9 control cells. Additionally, PTPRC-KO clone A was used to re-express PTPRC by lentiviral transduction (KO A + PTPRC; control: KO A + EV (empty vector)) (D, E, F). PTPRG and PTPRC protein levels of engineered cells are shown in Figures 5 and 6 respectively. Each dot represents the IC₅₀ value determined in one independent experiment with quadruplicate technical replicas, black bars show the median of n = 6 independent experiments. ns (not significant) if p > 0.05; ^* if p < 0.05. Comparison with the respective EV or control was performed with the Wilcoxon matched pairs test.